CJC-1295 (no-DAC) + Ipamorelin
Why this combination
This is the classic growth-hormone-secretagogue pairing. CJC-1295 without DAC (a GHRH analog, also called Mod GRF 1-29) increases the amount of GH released per pulse, while Ipamorelin (a selective ghrelin-receptor agonist) triggers a clean GH pulse with minimal effect on cortisol or prolactin.
Used together they act on two different receptors to amplify the body's own pulsatile GH release rather than supplying exogenous GH. The combination is one of the best-tolerated GH-secretagogue stacks in community use.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| CJC-1295 no-DAC | 100 mcg | 1–3× daily | Often dosed before bed on an empty stomach. |
| Ipamorelin | 100 mcg | 1–3× daily | Commonly matched 1:1 with CJC-1295 no-DAC. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
CJC-1295 no-DAC — reconstitute a 5 mg vial with 3 mL → 1,666.7 mcg/mL. A 100 mcg dose is 0.06 mL (6 units); 200 mcg is 0.12 mL (12 units). (Using 3 mL keeps the small 100 mcg dose above the hard-to-measure 5-unit threshold.)
Ipamorelin — 5 mg + 3 mL → 1,666.7 mcg/mL; 100 mcg = 0.06 mL (6 units), same as above.
Pre-blended (single vial)
Because both are dosed at 100 mcg, they blend cleanly: combine CJC-1295 no-DAC 5 mg + Ipamorelin 5 mg in one vial and add 3 mL bacteriostatic water.
Each compound is then 1,666.7 mcg/mL, so a single 0.06 mL draw (6 units) delivers 100 mcg of each — one injection for the full stack.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Commonly 12+ weeks, often 5 days on / 2 days off; benefits build over time.
- Compared to alternatives
- Versus CJC-1295 with DAC, the no-DAC form gives shorter, more physiologic pulses (favored for the bedtime pulse) but requires more frequent dosing. Versus Tesamorelin + Ipamorelin, this pairing is more general-purpose, whereas tesamorelin has specific visceral-fat data.
Sources & references
Frequently asked questions
Why use a 1:1 ratio?
Both compounds are conventionally dosed around 100 mcg, and dosing them together leverages two different receptors (GHRH and ghrelin) for a larger combined GH pulse. The 1:1 convention also makes pre-blending into a single vial straightforward.
Why dose before bed?
The largest natural GH pulse occurs during early sleep, so a bedtime dose is timed to amplify that physiologic pulse.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
Tesamorelin + Ipamorelin
This pairing follows the classic GH-secretagogue logic of combining a GHRH analog with a ghrelin-receptor (GHRP) agonist, but upgrades the GHRH side to tesamorelin — a stabilized GHRH analog that is the only growth-hormone-axis peptide in this category with FDA-approved human efficacy data, specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy (marketed as Egrifta). The premise is that tesamorelin amplifies the size of each GH pulse at the pituitary while ipamorelin, a highly selective ghrelin-receptor agonist, both adds a second, independent pulse trigger and suppresses somatostatin, the brake on GH release.